PBYI: Strong revenue growth and promising clinical progress with biomarker-driven cancer therapies

NERLYNX continues to show strong revenue growth and expanded guidance, while alisertib advances in phase II trials for breast and lung cancer with promising biomarker-driven results. Additional interim data and a focus on targeted patient populations are expected to drive future development.Based o…